Story
Argenx to Acquire Forte Biosciences for $2.2 Billion, Targeting Autoimmune Drug Candidate
Summary
The all-cash deal values Forte Biosciences at $77 per share, a significant premium driven by the potential of its lead antibody program, FB102, for treating autoimmune diseases like vitiligo.
Global immunology company argenx announced Monday it will acquire Forte Biosciences in an all-cash transaction valued at approximately $2.2 billion, a move that sent Forte's shares soaring. The acquisition is centered on Forte's promising first-in-class antibody treatment for autoimmune diseases, FB102.
Deal Details
Under the terms of the merger agreement, argenx will launch a cash tender offer to acquire all outstanding shares of Forte Biosciences (NASDAQ: FBRX) for $77 per share. This price represents a significant premium of approximately 86% to Forte's volume-weighted average price since the company announced positive clinical data on July 9, 2026.
The transaction will be funded entirely with cash on hand and is not subject to any financing conditions. The boards of directors of both companies have approved the deal, which is expected to close in the third quarter of 2026, pending customary closing conditions including regulatory clearance.
Strategic Rationale
The acquisition's primary driver is FB102, Forte's lead drug candidate. FB102 is a first-in-class anti-CD122 antibody designed to target pathogenic T-cells and NK-cells, which play a role in various autoimmune conditions. The program is seen as a strategic complement to argenx's existing portfolio of antibody-based therapies.
AdForte Biosciences has reported positive clinical trial results for FB102, bolstering its value:
- Vitiligo: Recently reported positive Phase 1b data demonstrating a statistically significant treatment benefit.
- Celiac Disease: Shared positive Phase 1b data last year, with Phase 2 data anticipated in the second half of 2026.
Beyond these indications, argenx noted that FB102 has potential applications in treating alopecia areata and other autoimmune diseases.
Market Impact
Following the announcement, investors reacted positively to the acquisition terms. Shares of Forte Biosciences surged 39% in Monday trading, reflecting the substantial premium offered by argenx.
Read next
More on Stocks
White House Blocks CNN from Air Force One Press Pool, Washington Post Reports
The White House has reportedly denied CNN a spot on Air Force One for President Donald Trump's upcoming trip to Tennessee, according to The Washington Post. The move marks a significant development in the administration's contentious relationship with the news network.
Morgan Stanley Public Finance Co-Head Zach Solomon Departs for TD Securities
Zach Solomon, co-head of public finance investment banking at Morgan Stanley, has joined TD Securities amid the Canadian bank's expansion in the U.S. municipal bond market. The move follows the recent Chapter 11 bankruptcy filing of a key client, Brightline.
OpenAI Models Accessed Public Data From SEC, Census Bureau Websites, Bloomberg Reports
OpenAI's AI models reportedly interacted with publicly available data on U.S. government websites, including the SEC and Census Bureau, prompting the company to launch a review of the activity.
Citigroup Targets Over $3 Billion Banamex IPO for January, Bloomberg Reports
Citigroup is reportedly preparing for an initial public offering of its Mexican retail unit, Banamex, that could raise over $3 billion and is targeted for January. The move represents a major step in the bank's multi-year strategy to exit international consumer banking operations.